Investment Rating - The report gives a "Buy" rating for the company for the first time, with a target price of 51.48 CNY based on a 52x P/E ratio for 2025 [5][8]. Core Insights - The company is a leading player in non-clinical safety evaluation in China, backed by strong resources from its parent company, China National Pharmaceutical Group [12][16]. - The CRO (Contract Research Organization) market is expected to see growth driven by increasing demand for innovative drug development and favorable policies [12][44]. - The company has a comprehensive range of GLP (Good Laboratory Practice) certifications, enabling it to provide international standard services [21][22]. Financial Forecast and Investment Recommendations - The projected EPS for 2025-2027 is 0.99, 1.16, and 1.42 CNY respectively, indicating significant growth potential due to the company's competitive advantages [5]. - Revenue is expected to grow from 1,038 million CNY in 2023 to 1,490 million CNY in 2027, with a CAGR of approximately 14.8% [7]. - The company's net profit is forecasted to increase from 194 million CNY in 2023 to 200 million CNY in 2027, reflecting a strong growth trajectory [7]. Company Overview - The company specializes in innovative drug research outsourcing services and ranks third in the domestic preclinical safety evaluation sector [12][29]. - It has successfully assisted in the research services of nearly 200 innovative drugs, covering a wide range of drug types including small molecules and ADCs (Antibody-Drug Conjugates) [12][31]. Market Trends - The CRO market is anticipated to maintain a double-digit growth rate, with global market size projected to reach 126 billion USD by 2028 [44][47]. - The report highlights a rebound in overseas demand for CRO services and an upward cycle in the domestic market, driven by improved financing conditions and increased willingness of domestic pharmaceutical companies to invest in innovative drug development [12][44].

Group 1 - The three major indices experienced fluctuations and declines, while the pharmaceutical and biotechnology sector showed resilience, with significant gains in innovative drugs, brain-computer interfaces, and recombinant proteins [1] - The Science and Technology Innovation Pharmaceutical Index ETF (588700) rose by 0.60%, with a trading volume exceeding 20 million yuan and a turnover rate of over 8%. Notable component stocks included Shouyao Holdings-U, which increased by over 6%, along with Yuan Dong Biological, Oriental Bio, and Haoyuan Pharmaceutical [1] - The Science and Technology Innovation Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals and related fields, reflecting the overall performance of representative biopharmaceutical companies listed on the Science and Technology Innovation Board [1] Group 2 - Guosheng Securities indicated that the domestic CRO industry is nearing a critical turning point, with the potential for layout opportunities arising from policy changes and supply-demand restructuring [2] - The CRO sector has faced operational fluctuations due to external environmental changes, but long-term policy support is expected to drive demand growth once financing issues for innovative drug companies are resolved [2] - The market share of leading CRO companies has expanded to some extent following a period of industry clearing [2] Group 3 - According to Jiao Yin International, multiple significant data on domestic innovative drugs will be presented at the 2025 ASCO conference, highlighting opportunities for innovation and performance resonance [3] - Chinese pharmaceutical companies showcased 71 original research results, with 11 presented in LBA format, indicating a potential surge in interest for the innovative drug sector [3] - The investment attractiveness of the innovative drug sector is notable, with valuations significantly below historical averages and institutional holdings at low levels, supporting the continued implementation of favorable policies [3]